Use and impact of herpes zoster prophylaxis in myeloma patients treated with proteasome inhibitors

Siyang LengDepartment of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA; Correspondence[email protected]

http://orcid.org/0000-0002-4852-7114

Suzanne LentzschDepartment of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA; ;Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA;

http://orcid.org/0000-0003-1708-7344

Yanhan ShenDepartment of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY, USA;

Wei-Yann TsaiDepartment of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY, USA;

Jason Dennis WrightHerbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA; ;Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA; ;Department of Obstetrics and Gynecology, College of Physicians and Surgeons, Columbia University, New York, NY, USA

Dawn Lauryn HershmanDepartment of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA; ;Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA; ;Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA;

Alfred I. NeugutDepartment of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA; ;Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA; ;Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA;

show all

Click to increase image sizeClick to decrease image size

Acknowledgements

This work was supported by the National Cancer Institute under Grants R25 CA094061 (Dr. Leng), R01 CA166084 (Dr. Hershman), and R01 CA169121 (Dr. Wright).

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2018.1429605.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Use and impact of herpes zoster prophylaxis in myeloma patients treated with proteasome inhibitors

Information for

Open access

Opportunities

Help and information

Use and impact of herpes zoster prophylaxis in myeloma patients treated with proteasome inhibitors

Acknowledgements

Potential conflict of interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature